A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above. - Trial NCT06342349
Access comprehensive clinical trial information for NCT06342349 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Institute Of Biological Products and is currently Not yet recruiting. The study focuses on Influenza. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Institute Of Biological Products
Timeline & Enrollment
Phase 1
Mar 31, 2024
Dec 30, 2024
Primary Outcome
Solicited Adverse Events (AEs),Unsolicited Adverse Events,Serious Adverse Events (SAE)
Summary
To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus
 split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06342349
Non-Device Trial